Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 57.87 1.5 (2.66%) Market Cap: 5.33 Bil Enterprise Value: 4.46 Bil PE Ratio: 0 PB Ratio: 12.33 GF Score: 74/100

Ultragenyx Pharmaceutical Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 10, 2020 / 07:00PM GMT
Release Date Price: $117.48 (+3.31%)
Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Okay. Welcome, everybody. I am your guide this next 30 minutes with Ultragenyx. I'm Marty Auster. I'm the lead Smid cap biotech analyst at Crédit Suisse. Welcome to our Ultragenyx fireside chat at the 29th Annual Crédit Suisse Healthcare Conference and the first virtual one.

I've got Dr. Emil Kakkis here, the CEO and Founder of Ultragenyx. I want to thank everyone for joining us today. If anybody had any questions during this fireside, I'm happy to work those into the conversation. Shoot me an e-mail. There should be a tab on your screen to do so or just send me an e-mail straight through, and I'll check and get to them during the fireside.

Questions & Answers

Martin Douglas Auster;dit Suisse AG
CrÃ;Research Division - Research Analyst

© -

Emil, let me hand it over to you, and let me start with -- I noticed when I was prepping questions for this, that you guys are a decade in as of this summer. I'm curious what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot